Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I

Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7134-8. doi: 10.1073/pnas.89.15.7134.

Abstract

Atherosclerosis is a major cause of morbidity and mortality in developed countries. In humans the risk of atherosclerosis is inversely correlated with plasma levels of high density lipoprotein (HDL). As a step in determining whether the experimental reduction of plasma HDL level will increase susceptibility to atherosclerosis, we have used gene targeting in embryonic stem cells to produce mice lacking apolipoprotein A-I, the major protein component of HDL particles. Mice homozygous for the disrupted gene have no plasma apolipoprotein A-I detectable by double immunodiffusion; their total plasma cholesterol and HDL-cholesterol levels after overnight fasting are reduced to about one-third and one-fifth of normal levels, and they are grossly deficient in alpha-migrating HDL particles.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Apolipoprotein A-I / deficiency
  • Apolipoprotein A-I / genetics*
  • Apolipoprotein A-I / metabolism
  • Apolipoprotein C-III
  • Apolipoproteins C / genetics
  • Arteriosclerosis / genetics
  • Blotting, Southern
  • Cell Survival / drug effects
  • Cells, Cultured
  • Chimera
  • Cholesterol / blood
  • Cholesterol, HDL / blood*
  • DNA / genetics
  • DNA / isolation & purification
  • Exons
  • Ganciclovir / pharmacology
  • Heterozygote
  • Homozygote
  • Mice
  • Mice, Inbred Strains
  • Mice, Transgenic
  • Plasmids
  • Recombination, Genetic
  • Restriction Mapping
  • Stem Cells / physiology

Substances

  • Apolipoprotein A-I
  • Apolipoprotein C-III
  • Apolipoproteins C
  • Cholesterol, HDL
  • DNA
  • Cholesterol
  • Ganciclovir